GW Research Ltd clinical trials
Acquired by Jazz Pharmaceuticals, May 5, 2021 · source ↗
The registry lists 5 studies whose lead sponsor is GW Research Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 3, 2022.
Before and after it joined Jazz Pharmaceuticals
- First submitted before GW Research Ltd became part of Jazz Pharmaceuticals
- 5
- First submitted after GW Research Ltd became part of Jazz Pharmaceuticals
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- GW Research Ltd5 studies
Something wrong with this grouping? Tell us on the Jazz Pharmaceuticals page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Jazz Pharmaceuticals studies →
- An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut SyndromesCompletedNCT02224573Phase 3
Sponsor listed in the registry: GW Research Ltd · First submitted before GW Research Ltd became part of Jazz Pharmaceuticals
- A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)CompletedNCT01562314Phase 2
Sponsor listed in the registry: GW Research Ltd · First submitted before GW Research Ltd became part of Jazz Pharmaceuticals
- Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver DiseaseCompletedNCT01284634Phase 2
Sponsor listed in the registry: GW Research Ltd · First submitted before GW Research Ltd became part of Jazz Pharmaceuticals
- Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.WithdrawnNCT01868048Phase 3
Sponsor listed in the registry: GW Research Ltd · First submitted before GW Research Ltd became part of Jazz Pharmaceuticals
- Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With OlanzapineTerminatedNCT01491490Phase 2
Sponsor listed in the registry: GW Research Ltd · First submitted before GW Research Ltd became part of Jazz Pharmaceuticals